8 results about "Amniotic stem cells" patented technology

The invention relates to the field of biological medicine, in particular to a shRNA (short hairpin Ribonucleic Acid) inhibitor expressed by Engrailed-1 protein, an RNAi (Ribonucleic Acid Interfere) exosome as well as a preparation method and application of the RNAi exosome. According to the shRNA inhibitor expressed by the Engraled-1 protein, a nucleotide sequence as shown in SEQ ID NO.1 is selected as a target sequence, the shRNA designed according to the target sequence is high in specificity, and expression of the Engraled-1 protein can be remarkably inhibited. Meanwhile, through the shRNA inhibitor provided by the invention, the RNAi technology is utilized, and the amniotic stem cell exosome is used as a carrier, so that the Engrailed-1 protein can be accurately and remarkably inhibited, the problems of poor curative effect and high cost of a traditional scar repair technology are avoided, and scar formation caused by the Engrailed-1 protein is expected to be relieved or cured.

The invention relates to the technical field of biological medicine, in particular to a shRNA inhibitor expressed by CD36 molecules, an RNAi exosome and a preparation method and application of the shRNA inhibitor and the RNAi exosome. According to the shRNA inhibitor expressed by the CD36 molecule, a nucleotide sequence as shown in SEQ ID NO.1 is selected as a target sequence, the shRNA designed according to the target sequence is high in specificity, and expression of the CD36 molecule can be remarkably inhibited. Meanwhile, through the shRNA inhibitor provided by the invention, by utilizing an RNAi technology and taking the amniotic stem cell exosome as a carrier, accurate and remarkable inhibition of CD36 molecules can be realized, the problems of poor curative effect and high cost of a traditional scar repair technology are avoided, and scar formation caused by the CD36 molecules is expected to be relieved or cured.

The invention relates to the technical field of biological medicines, in particular to an amniotic stem cell preparation and application thereof in treating erectile dysfunction. The preparation method of the amniotic stem cell preparation comprises the following steps: adding amniotic stem cells, the active extract, butanediol, glycerol, trehalose, glucose, amino acid and vitamins into normal saline containing human umbilical cord blood plasma, uniformly mixing to obtain the amniotic stem cell preparation, and storing the amniotic stem cell preparation in a liquid nitrogen tank. The prepared amniotic stem cell can significantly increase the ICP / MAP ratio, improve the activity of NOS and GC, increase the content of NO and cGMP, effectively improve erectile dysfunction and repair damaged tissues.

The application discloses an optimized method for preparing amniotic membrane stem cell membrane pieces, relates to the technical field of tissue engineering and regenerative medicine, and significantly shortens the preparation period of the amniotic membrane stem cell membrane pieces by adding nicotinamide adenine dinucleotide (NAD+) and a precursor compound beta-nicotinamide mononucleotide (NMN) in a traditional cell membrane piece culture medium, combining with vitamin C (VC) and a mechanical scratching method. More importantly, the method can effectively reduce the surface expression amount of stem cell CD34 in the membrane pieces, from about 2.04% in a conventional method to below 0.12%, and the prepared stem cell membrane pieces have lower immunogenicity and more definite mesenchymal stem cell characteristics, so that the safety and effectiveness of the stem cell membrane pieces in clinical transplantation application are greatly improved.

This invention provides a method for producing induced pluripotent stem cells. [Solution] The present disclosure includes the step of producing induced pluripotent stem cells by expressing exogenous nucleic acids encoding proteins OCT3 / 4, SOX2, KLF4, LIN28, and L-MYC, as well as p53-shRNA, in umbilical cord amniotic stem cells under conditions suitable for reprogramming stem cells. The present disclosure also includes the induced pluripotent stem cell population obtainable by this method, the induced pluripotent stem cell population obtained by this method, a pharmaceutical composition containing the induced pluripotent stem cells of the present invention, a method for differentiating the induced pluripotent stem cells of the present invention, a pharmaceutical composition containing the differentiated induced pluripotent stem cells obtained by this method, and a method for treating congenital or acquired degenerative disorders in a subject, comprising the step of administering target cells differentiated from pluripotent stem cells to the subject.

Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.

The invention provides a stem cell preparation for treating premature ovarian failure, which is composed of human amniotic stem cells and a matrix solution, and the matrix solution is composed of dextran 40 glucose injection, 1-3% of human albumin, 1-10% of compound amino acid injection (18AA), 1-5% of ginkgo leaf extract injection, 1-5 [mu] M of reduced glutathione and 10-20 [mu] g / ml of coenzyme I, the stem cell preparation prepared from the human amniotic stem cells and the matrix solution can well maintain the activity, dryness and uniformity of the stem cells, the components are clear, heterologous animal serum is not contained, after the stem cell preparation is stored for 96 h at the temperature of 4-8 DEG C, the cell morphology is uniform, the survival rate is still kept to be 90% or above, and the stem cell preparation has a good treatment effect on premature ovarian failure.

Provided herein include methods, compositions, isolated cells, cell models, and kits suitable for use in profiling various cell types in amnion including amnion epithelial cells, amnion mesenchymal cells, fibroblasts, macrophages, as well as amnion stem cells including amnion epithelial stem cells and amnion mesenchymal stem cells. The present disclosure also discloses novel markers for various cell types in human amnion, including marker genes, transcription factors and signaling molecules associated with various stages of amniotic development. The methods, cell models, and gene signatures disclosed herein can be used for a variety of research, diagnostic, or therapeutic applications.